NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review)

Limited trial; not open ETCTN-wide; Version Date: October 20, 2019

Skin and Other Melanoma

Kidney transplant recipients

Melanoma

Basal cell carcinoma

Kidney transplant recipients with melanoma, basal cell carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma or MSI-high cancer

Metastatic melanoma, not otherwise specified

BRAF-mutant melanoma

Basal cell carcinoma

Unresectable or Metastatic Cancers

Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers

ETCTN Trials by Disease/Treatment Area: Skin and Other Melanoma

9466: Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only)

9676: A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase: Pt 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

10214: A Phase II Trial of NK-377 Plus ZV-Aflibercept in Patients with Advanced Solid Tumors

10215: A Phase II Study of T-VEC Followed by T-VEC + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

9467: Phase III Study of Olaparib for Kidney Transplant Recipients with Melanoma, Basal Cell Carcinoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma or MSI-high Cancer

9468: Phase III Study of Olaparib for Kidney Transplant Recipients with Unresectable or Metastatic Cancers

9446: Phase III Study of Olaparib for Kidney Transplant Recipients with Melanoma, Basal Cell Carcinoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma or MSI-high Cancer

10057: A Phase II Study of T-VEC Followed by T-VEC + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors